CordenPharma Expands Service Offerings

July 1, 2016
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016, Volume 11, Issue 7

The company expanded its services to include oligonucleotide API development and manufacturing and received approval for its Caponago manufacturing facility.

On July 1, 2016, CordenPharma announced that it has expanded its services to include oligonucleotide API development and manufacturing. The investment was initiated by CordenPharma Colorado and is expected to be complete before the end of 2016, the company said in a press announcement. Corden’s portfolio for API and drug products includes peptides, lipids, and carbohydrates for API manufacturing and development. In late June, the Italian Medicines Agency approved Corden’s sterile injectable facility in Caponago, Italy. The manufacturing facility, which was recently completed, will support customer development and commercial programs by providing service in aseptic filling of liquid and lyophilized vials, and pre-filled syringes. This adds to the facility’s existing terminal sterilization capabilities.

Source: Corden Pharma